Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PILVE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Trastuzumab-L2-TL
|
|||||
| Synonyms |
Tra-L2-TL
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.39
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Triptolide
|
Payload Info | ||||
| Therapeutic Target |
Nuclear factor NF-kappa-B p105 subunit (NFKB1)
|
Target Info | ||||
| Linker Name |
BVP-PEG3-diamine
|
Linker Info | ||||
| Conjugate Type |
All the linker-drugs contain a BVP group for the site-specific conjugation to the disulfides of antibody by re-bridging approach.
|
|||||
| Combination Type |
L2-TL
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.